Approved Nanomedicine against Diseases

Jia, Yuanchao; Jiang, Yuxin; He, Yonglong; Zhang, Wanting; Zou, Jiahui; Magar, Kosheli Thapa; Boucetta, Hamza; Teng, Chao; He, Wei

doi:10.3390/pharmaceutics15030774

Cited by 48 publications

(21 citation statements)

References 229 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To overcome these hurdles, liposomes offer many advantages as antibiotic nanocarriers. These lipid-based nanosystems may reduce dose and frequency of administrations, prevent enzymatic degradation, avoid drug efflux mechanisms, and overcome outer membranes [ 18 , 31 , 73 , 74 ]. In the case of RFB, previous studies in a murine model of disseminated Mycobacterium tuberculosis infection demonstrated a significantly superior antimycobacterial effect of RFB-loaded liposomes in the spleen and liver, compared to free antibiotic [ 28 ].…”

Section: Resultsmentioning

confidence: 99%

Liposomal Rifabutin—A Promising Antibiotic Repurposing Strategy against Methicillin-Resistant Staphylococcus aureus Infections

Pinho,

Ferreira,

Coelho

et al. 2024

Pharmaceuticals

View full text Add to dashboard Cite

Methicillin-resistant Staphylococcus aureus (M RSA) infections, in particular biofilm-organized bacteria, remain a clinical challenge and a serious health problem. Rifabutin (RFB), an antibiotic of the rifamycins class, has shown in previous work excellent anti-staphylococcal activity. Here, we proposed to load RFB in liposomes aiming to promote the accumulation of RFB at infected sites and consequently enhance the therapeutic potency. Two clinical isolates of MRSA, MRSA-C1 and MRSA-C2, were used to test the developed formulations, as well as the positive control, vancomycin (VCM). RFB in free and liposomal forms displayed high antibacterial activity, with similar potency between tested formulations. In MRSA-C1, minimal inhibitory concentrations (MIC) for Free RFB and liposomal RFB were 0.009 and 0.013 μg/mL, respectively. Minimum biofilm inhibitory concentrations able to inhibit 50% biofilm growth (MBIC50) for Free RFB and liposomal RFB against MRSA-C1 were 0.012 and 0.008 μg/mL, respectively. Confocal microscopy studies demonstrated the rapid internalization of unloaded and RFB-loaded liposomes in the bacterial biofilm matrix. In murine models of systemic MRSA-C1 infection, Balb/c mice were treated with RFB formulations and VCM at 20 and 40 mg/kg of body weight, respectively. The in vivo results demonstrated a significant reduction in bacterial burden and growth index in major organs of mice treated with RFB formulations, as compared to Control and VCM (positive control) groups. Furthermore, the VCM therapeutic dose was two fold higher than the one used for RFB formulations, reinforcing the therapeutic potency of the proposed strategy. In addition, RFB formulations were the only formulations associated with 100% survival. Globally, this study emphasizes the potential of RFB nanoformulations as an effective and safe approach against MRSA infections.

show abstract

Section: Resultsmentioning

confidence: 99%

Liposomal Rifabutin—A Promising Antibiotic Repurposing Strategy against Methicillin-Resistant Staphylococcus aureus Infections

Pinho,

Ferreira,

Coelho

et al. 2024

Pharmaceuticals

View full text Add to dashboard Cite

show abstract

“…To date, there are more than 100 nanomedicines approved on the market, mainly for cancer therapy (53%) and infection (14%) 72,73 . However, there are several challenges limited the development of nanomedicine, and the applications of nanoparticles in metabolic diseases are still far from fully developed.…”

Section: Discussionmentioning

confidence: 99%

Fabricating a hepatocyte-targeted fullerene derivative as a new lipid droplet regulator

Li,

Zou,

Wan

et al. 2023

Preprint

View full text Add to dashboard Cite

Lipid droplets (LDs) are crucial organelles in organisms and hold a critical function in modulating intracellular lipid metabolism and bioenergetic regulation. The homeostasis of LDs directly participates in the onset and progression of non-alcoholic steatohepatitis (NASH) and other metabolic disorders. However, no pharmacological approaches have been developed to target LDs-related dysfunction for metabolic diseases. Here, we systemically screened biocompatible nanoparticles for anti-LDs formation capacities, and identified a carboxyl fullerene derivative, named four malonate groups-substituted C70 fullerene (QF70), as the most potent lead. Notably, QF70 could be directly internalized into hepatocytes and facilitate lysosomal degradation of perilipin-2 (PLIN2), the key molecule in LDs formation and stability. More importantly, oral administration of QF70 robustly blocked both diet- and Leptin deficiency-induced NASH development with significant improvement in obesity and insulin resistance. We further validated the clinical application potential of QF70 in NASH related metabolic disorders in a non-primate model. To our knowledge, this is the first-in-class demonstration for a nanoparticle based agent as a LDs homeostasis-targeted therapeutic to treat metabolic diseases.

show abstract

“…The combination of drugs and nanomaterials will provide hope for patient survival ( Van der Meel et al, 2019 ; Jia et al, 2023 ). Multi-drug combination is one of the important means to improve anti-cancer efficacy, and it is also a general trend in the field of drug research and development ( Detappe et al, 2023 ).…”

Section: Conclusion and Future Prospectsmentioning

confidence: 99%

Advancement of regulating cellular signaling pathways in NSCLC target therapy via nanodrug

Li,

Huang

et al. 2023

Front. Chem.

View full text Add to dashboard Cite

Lung cancer (LC) is one of the leading causes of high cancer-associated mortality worldwide. Non-small cell lung cancer (NSCLC) is the most common type of LC. The mechanisms of NSCLC evolution involve the alterations of multiple complex signaling pathways. Even with advances in biological understanding, early diagnosis, therapy, and mechanisms of drug resistance, many dilemmas still need to face in NSCLC treatments. However, many efforts have been made to explore the pathological changes of tumor cells based on specific molecular signals for drug therapy and targeted delivery. Nano-delivery has great potential in the diagnosis and treatment of tumors. In recent years, many studies have focused on different combinations of drugs and nanoparticles (NPs) to constitute nano-based drug delivery systems (NDDS), which deliver drugs regulating specific molecular signaling pathways in tumor cells, and most of them have positive implications. This review summarized the recent advances of therapeutic targets discovered in signaling pathways in NSCLC as well as the related NDDS, and presented the future prospects and challenges.

show abstract

Approved Nanomedicine against Diseases

Cited by 48 publications

References 229 publications

Liposomal Rifabutin—A Promising Antibiotic Repurposing Strategy against Methicillin-Resistant Staphylococcus aureus Infections

Liposomal Rifabutin—A Promising Antibiotic Repurposing Strategy against Methicillin-Resistant Staphylococcus aureus Infections

Fabricating a hepatocyte-targeted fullerene derivative as a new lipid droplet regulator

Advancement of regulating cellular signaling pathways in NSCLC target therapy via nanodrug

Contact Info

Product

Resources

About